Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Sunshine Biopharma (SBFM) over the last 14 years, with Q3 2025 value amounting to $75536.0.

  • Sunshine Biopharma's Cash from Financing Activities fell 9613.39% to $75536.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 1786.42%. This contributed to the annual value of $9.3 million for FY2024, which is 17118.0% up from last year.
  • Sunshine Biopharma's Cash from Financing Activities amounted to $75536.0 in Q3 2025, which was down 9613.39% from $3.6 million recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Cash from Financing Activities peaked at $29.1 million during Q2 2022, and registered a low of -$2.1 million during Q4 2022.
  • Moreover, its 5-year median value for Cash from Financing Activities was $826324.0 (2021), whereas its average is $3.3 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 875841.78% in 2022, then surged by 1273070.71% in 2025.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Cash from Financing Activities stood at -$23664.0 in 2021, then tumbled by 8758.42% to -$2.1 million in 2022, then surged by 98.54% to -$30519.0 in 2023, then soared by 6542.34% to $2.0 million in 2024, then tumbled by 96.16% to $75536.0 in 2025.
  • Its Cash from Financing Activities was $75536.0 in Q3 2025, compared to $3.6 million in Q2 2025 and $338137.0 in Q1 2025.